Spots Global Cancer Trial Database for A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
Official Title: An Open-Label, Randomized Phase IB/II Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
Study ID: NCT06055075
Conditions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of forimtamig when administered alone or in combination with carfilzomib or daratumumab or other combination partners in participants with relapsed or refractory multiple myeloma (r/r MM). The study consists of two phases: a dose exploration phase and a dose-expansion phase.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology, Woolloongabba, Queensland, Australia
Royal Adelaide Hospital, Adelaide, South Australia, Australia
Hamilton Health Sciences, Hamilton, Ontario, Canada
Aarhus Universitetshospital Skejby; Blodsygdomme - Klinisk Forsknings Enhed, Aarhus N, , Denmark
Rigshospitalet; Hæmatologisk Klinik, Klinisk Afprøvnings Team KAT, København Ø, , Denmark
Odense Universitetshospital; Hæmatologisk Afdeling, Odense C, , Denmark
CHRU Lille - Hôpital Claude Huriez; Service des Maladies du Sang, Lille, , France
CHU NANTES - Hôtel Dieu; Service d'Hematologie Clinique, Nantes, , France
Klinikum Nürnberg Nord; Klinik für Innere Medizin 5, Schwerpunkt Onkologie / Hämatologie, Nürnberg, , Germany
IRCCS Istituto Nazionale dei Tumori di Napoli - Pascale Ematologia Oncologica, Napoli, Campania, Italy
Policlinico S.Orsola-Malpighi;Istituto di Ematologia "Seragnoli", Bologna, Emilia-Romagna, Italy
Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia, Rozzano, Lombardia, Italy
Seoul National University Hospital, Seoul, , Korea, Republic of
Samsung Medical Center, Seoul, , Korea, Republic of
Seoul St Mary's Hospital, Seoul, , Korea, Republic of
New Zealand Clinical Research - Auckland, Auckland, , New Zealand
Hospital Universitario Marques de Valdecilla; Servicio de Hematologia, Santander, Cantabria, Spain
Clinica Universitaria de Navarra; Servicio de Hematologia, Pamplona, Navarra, Spain
Clinica Universidad de Navarra Madrid; Servicio de Hematología, Madrid, , Spain
Contact Details
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
